The pharmaceutical industry has never been better at discovering medicines. Target identification, platform technologies, and AIassisted trial design have transformed what is scientifically possible, and the pipeline has never been fuller.

Yet across boardrooms and operating committees, the same concerns surface year after year: timelines that slip despite best intentions, regulatory submissions that require costly revision, clinical trials that recruit slowly and yield data late, and commercial launches that fail to communicate an asset’s full value to the stakeholders who determine its uptake.